Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.46 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23187755 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL25647927 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL23104998 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL22348843 | 0.94 | POLB (0.55) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL22348842 | 0.94 | POLB (0.55) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL22348858 | 0.93 | POLB (0.53) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL22348859 | 0.93 | POLB (0.53) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL20845806 | 0.93 | CYP3A4 (0.53) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL19815762 | 0.93 | POLB (0.57) | CYP3A4CYP2C9POLBP2RY2P2RY4 | |
| SCHEMBL17451201 | 0.93 | POLB (0.57) | CYP3A4CYP2C9POLBP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | AVALO THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10745435-B2 | Nucleic acid prodrugs | CERECOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101923-A1 | NUCLEIC ACID PRODRUGS | NUDT1, PNP, TYMP | CYP3A4 1074/4885CYP2C9 983/4885POLB 82/4885 |
| US-10745435-B2 | Nucleic acid prodrugs | POLRMT, FPGS, POLN | CYP3A4 1542/4885CYP2C9 1252/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.